U.S. Pulse Oximeters Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

U.S. Pulse Oximeters Market Trends and Insights

Rising COPD, Asthma, and Sleep Apnea Burden Driving Oxygen Saturation Monitoring

Chronic respiratory diseases are driving demand in the United States pulse oximeters market. In 2024, 4.2% of adults in the United States were diagnosed with COPD, emphysema, or chronic bronchitis. Additionally, 83.7 million adults, or 32.4% of the adult population, were estimated to have obstructive sleep apnea, with many cases undiagnosed. Severe and moderate cases, accounting for 18% and 30% respectively, are increasing the need for clinical-grade overnight pulse oximetry.^{[2]Respiratory Medicine, “Unmasking Obstructive Sleep Apnea, Estimated Prevalence and Impact in the United States,” Respiratory Medicine, resmedjournal.com} Sleep apnea screening is the fastest-growing application, with a 6.98% CAGR projected through 2031. Nonin Medical’s 2025 launch of its Nonin Health platform addresses remote overnight testing for over 1.5 million Americans requiring supplemental oxygen. Broader diagnoses and protocol adoption are expected to sustain long-term device demand.

FDA Pressure for Accuracy Across Skin Tones Elevating Premium Device Replacement

The FDA’s 2025 draft guidance significantly impacts the United States pulse oximeters market by increasing clinical study pool requirements and mandating diverse skin tone representation. These changes favor advanced multi-wavelength systems over older products, prompting hospitals to replace low-cost devices with next-generation platforms.^{[3]U.S. Census Bureau, “Older Adults Outnumber Children in Many States,” U.S. Census Bureau, census.gov} This shift is transforming routine replacement cycles into premium upgrade opportunities. Masimo’s MightySat Medical, cleared by the FDA in 2024, highlights the rising clinical expectations for consumer-accessible devices.

Remote Patient Monitoring Reimbursement Expanding Connected Pulse Oximeter Adoption

Medicare reimbursement policies are driving growth in the United States pulse oximeters market. Remote patient monitoring payments reached USD 536 million in 2024, a 31% increase from 2023, with nearly 1 million beneficiaries receiving services. CPT codes 99453 and 99454 support payments for device setup and monitoring, improving the economic case for connected device investments. Allowing auxiliary personnel to perform device setup further reduces onboarding costs, making connectivity features essential for manufacturers.

Shift From Spot-Check to Continuous Monitoring Restructuring the Device Mix

The United States pulse oximeters market is shifting toward continuous monitoring, projected to grow at a 7.12% CAGR through 2031, compared to spot-check mode, which held 55.66% of revenue in 2025. Demand for wearable devices in step-down units, hospital-to-home programs, and sleep testing is driving this growth. Connected and wireless technology is expanding at a 7.45% CAGR, integrating clinical monitoring with data transmission. Masimo’s Radius PPG, used with GE HealthCare’s Portrait Mobile platform, exemplifies this transition. Home healthcare, growing at an 8.10% CAGR, is also benefiting from the aging population, with 61.2 million Americans aged 65 and older in 2024.

Persistent Accuracy Variability Limiting Clinical Confidence in Edge Populations

Accuracy issues remain a significant challenge in the United States pulse oximeters market, particularly in scenarios involving motion, low perfusion, and darker skin tones. A 2026 study revealed that the Masimo MightySat Rx, a leading clinical fingertip device, recorded an Arms of 3.52% at oxygen saturation levels below 88%. This result approaches the upper limit of clinical acceptability, highlighting variability in confidence across patient groups and care settings. These challenges are most evident in ICUs, post-surgical wards, and home respiratory monitoring, where factors like poor circulation, movement-related noise, and skin-tone biases impact reliability. Additionally, a 2024 meta-analysis by the FDA reported a pooled mean overestimation of 1.52% in Black and African American patients, further emphasizing equity concerns. The market remains divided between premium devices with advanced algorithms and commodity products facing reliability issues.

Intensifying Regulatory Review Compressing Entry Windows and Raising Validation Costs

Increasing regulatory scrutiny is driving up entry costs in the United States pulse oximeters market. Under the FDA’s January 2025 draft guidance, companies must recruit at least 150 participants for desaturation studies and demonstrate performance across diverse skin tones using both objective and subjective methods. Large players like Masimo and Nonin Medical are better positioned to manage these requirements due to their established validation infrastructure. Smaller and mid-tier suppliers face greater challenges, especially with lower price points limiting cost recovery. Additionally, connected devices face stricter expectations regarding cybersecurity and interoperability. These factors are likely to reduce the number of new entrants in the market during the later years of the forecast period.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Fingertip Dominance Coexists With Handheld-Driven Field Expansion

In 2025, fingertip pulse oximeters captured 31.1% of the U.S. pulse oximeters market by product type, establishing themselves as the top revenue format. Their dominance stems from being cost-effective, easy to operate, and versatile for both clinical spot-checks and home monitoring. The segment gained traction when Masimo’s MightySat Medical, received FDA clearance for OTC sale in February 2024, marking a significant milestone in consumer accessibility. However, this broader access doesn't diminish the demand for hospital-grade products, as many clinical settings still prioritize stronger validation and seamless workflow integration.

Forecasted to grow at a 6.55% CAGR through 2031, handheld pulse oximeters are emerging as the fastest-growing product format in the U.S. market. Their primary users include home health aides, visiting nurses, and staff at ambulatory surgical centers, all of whom seek portability combined with enhanced functionality over basic fingertip models. Meanwhile, tabletop and bedside systems maintain their essential role in ICUs and step-down units, where fixed-position monitoring is routine. 

By Technology: Connected and Wireless Devices Outpace Incumbents on Hospital Adoption

In 2025, wearable pulse oximeters dominated the U.S. market, accounting for 25.6% of the revenue. Their prominence is largely attributed to the surge in home monitoring adoption during the pandemic. Wearables have carved a niche for themselves, excelling in continuous patient monitoring, sleep diagnostics, and remote care, outpacing traditional fixed or episodic formats. This established presence has also helped integrate home-based SpO2 tracking into routine monitoring, moving it away from being solely an emergency measure.

Forecasted to grow at a 7.45% CAGR through 2031, connected and wireless pulse oximeters are leading the charge among technology categories in the U.S. market. Health systems are gravitating towards devices that seamlessly transfer data into electronic medical records, nurse alert systems, and remote patient monitoring workflows, minimizing manual intervention. Masimo’s expanded partnership with Philips in September 2025 is a testament to this trend, as it weaves SET, Radius PPG, and AI-driven monitoring into Philips’ patient monitoring ecosystem, extending through 2026 and beyond. 

By Measurement Mode: Continuous Monitoring Compressing Spot-Check’s Share Lead

In 2025, spot-check monitoring commanded 55.66% of the revenue, solidifying its status as the leading mode in the U.S. pulse oximeters market. This dominance is a testament to the widespread use of periodic vital sign assessment tools in hospitals, emergency departments, and outpatient clinics. In many of these environments, episodic measurements suffice for the clinical pathways in use. Thus, while the growth of spot-check devices may decelerate in comparison to more connected models, they will continue to play a pivotal role in daily care delivery.

Continuous monitoring is set to outpace spot-check usage, with projections indicating a 7.12% CAGR growth through 2031 in the U.S. pulse oximeters market. The increasing need for uninterrupted oxygen saturation data in scenarios like post-surgical observation, COPD management, and home sleep testing drives this demand. Furthermore, support from CMS for remote patient monitoring bolsters this trend, as continuous data transmission aligns with reimbursable care workflows.

By Patient Age Group: Pediatric and Neonatal Validation Requirements Elevating Complexity

In 2025, adults accounted for 63.78% of revenue, solidifying their dominant position in the U.S. pulse oximeters market. This aligns with the U.S. demographic trends and the concentration of chronic respiratory diseases among middle-aged and older adults. As of 2024, Americans aged 65 and older numbered 61.2 million, constituting 18% of the total population, underscoring the sustained demand for adult monitoring. Data from the CDC highlighted that in 2024, 4.2% of U.S. adults were affected by conditions like COPD, emphysema, and chronic bronchitis, with prevalence rates being notably higher in nonmetropolitan areas.

Projected to grow at a 7.98% CAGR through 2031, the pediatric segment is the fastest-growing age group in the U.S. pulse oximeters market. This growth is driven by needs in neonatal intensive care, evaluations for pediatric sleep apnea, and post-operative monitoring. However, pediatric and neonatal devices come with heightened design and validation challenges. Factors like smaller fingers, thinner tissue, and variable perfusion necessitate distinct sensor designs compared to adult platforms. 

By End User: Home Healthcare’s Structurally Superior Growth Reflects Care-Setting Shift

In 2025, hospitals commanded 41.23% of the revenue, reinforcing their leading position in the U.S. pulse oximeters market. This dominance is attributed to the extensive use of hospital-grade monitoring in surgical suites, ICUs, recovery units, and vital sign workflows. Hospital procurement is often influenced by long replacement cycles, standardization choices, and multi-device contracts with integrated delivery networks. While hospitals remain a significant and stable value pool, their unit growth has plateaued in the broader U.S. pulse oximeters market.

Forecasted to expand at an 8.10% CAGR through 2031, home healthcare is emerging as the fastest-growing end-user category in the U.S. pulse oximeters market. This surge is bolstered by factors like Medicare's support for remote patient monitoring, earlier patient discharges, an aging population, and a growing preference for at-home recovery. In 2024, nearly 1 million Medicare beneficiaries availed of RPM services, with oxygen saturation monitoring being a key parameter. 

By Application: Sleep Apnea Screening Leads Growth as Respiratory Monitoring Anchors Revenue

In 2025, respiratory disease monitoring accounted for 35.45% of the revenue, making it the leading application in the U.S. pulse oximeters market. This segment encompasses a range of activities, from monitoring COPD exacerbations and managing asthma to ongoing respiratory surveillance in both institutional and home environments. The demand is underscored by the significant burden of respiratory diseases, with conditions like COPD, emphysema, and chronic bronchitis affecting 4.2% of U.S. adults in 2024. Given the recurring nature of respiratory disease management, there's a sustained demand for longer device use cycles and ongoing sensor replacements.

Forecasted to grow at a 6.98% CAGR through 2031, sleep apnea screening is emerging as the fastest-growing application in the U.S. pulse oximeters market. This growth is fueled by the vast pool of undiagnosed obstructive sleep apnea (OSA), estimated at 83.7 million U.S. adults in 2024. The application is also reaping benefits from a shift towards home sleep diagnostics, moving away from exclusive lab testing, with overnight oximetry playing a pivotal role. 

Geography Analysis

The United States pulse oximeters market exhibits regional demand variations. The South and Appalachian corridor face a higher respiratory disease burden, with 2024 COPD prevalence at 10.6% in nonmetropolitan areas compared to 5.4% in large metropolitan areas. States like West Virginia, Kentucky, Mississippi, and Alabama show increased per-capita demand for home monitoring devices and oxygen-related follow-ups. However, connected device adoption in rural Southern markets has been slower due to uneven RPM infrastructure, though cellular-enabled devices are bridging this gap by reducing reliance on fixed broadband.

The Northeast significantly influences procurement trends in the United States pulse oximeters market. States such as New York, Massachusetts, Pennsylvania, and New Jersey benefit from dense hospital networks, consolidated health systems, and early adoption of integrated monitoring platforms. These regions often set procurement benchmarks for the rest of the country. Additionally, an aging population, with older adults outnumbering children in states like Delaware and Pennsylvania in 2024, drives demand for hospital-grade devices and home healthcare monitoring solutions.

The Midwest is emerging as a growth hub for post-acute and home health applications in the United States pulse oximeters market. Aging rural populations, strong durable medical equipment networks, and high Medicare Advantage penetration are expanding RPM adoption. In the West, states like California, Washington, and Oregon lead in telehealth integration and app-connected monitoring. California’s diverse population emphasizes skin-tone accuracy in procurement, aligning with the FDA’s updated standards and pushing health systems toward compliant next-generation platforms with stricter data and privacy protocols.